MTOR and adrenal cortex carcinoma: Naing et al59 studied cixutumumab, a monoclonal antibody targeting IGF-1R, in combination with the mammalian target of rapamycin (mTOR) inhibitor temsirolimus in a phase I trial of 26 patients with metastatic ACC.